<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099604</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12226 ViZIR</org_study_id>
    <nct_id>NCT02099604</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C</brief_title>
  <acronym>ViZIR</acronym>
  <official_title>Efficacy and Safety of the Combination Vitamin D (Vit D), With Pegylated Interferon Alpha-2b (PEG-IFN)/Ribavirin (RBV) in Egyptian Patients With Untreated Chronic Hepatitis C: A Phase III Randomized Open-label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show the superiority of a 4 weeks lead-in phase of Vitamin D&#xD;
      followed by a 48 weeks combination of Vitamin D with PEG-IFN plus RBV in comparison with&#xD;
      standard PEG-IFN + RBV in untreated Egyptian patients with chronic hepatitis C, on the&#xD;
      sustained virological response (SVR) at 3 months after end of treatment (week 60).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - Method: Phase III, randomized, open-label superiority clinical trial, among Egyptian&#xD;
      patients with chronic hepatitis C.&#xD;
&#xD;
      - Treatment strategy: Vitamin D Arm: Vitamin D over a 4 weeks lead-in phase followed by&#xD;
      Vitamin D in combination with PEG-INF plus RBV during 48 weeks. Standard of Care Arm: PEG-INF&#xD;
      plus RBV during 48 weeks.&#xD;
&#xD;
      - Main outcome: Proportion of patients with Sustained Virological Response (SVR) as defined&#xD;
      by HCV RNA below the detection limit based on quantitative PCR 12 weeks after stopping&#xD;
      treatment.&#xD;
&#xD;
        -  Sample Size: 520 patients (260 per arm)&#xD;
&#xD;
        -  Enrollment period: 12 months&#xD;
&#xD;
        -  Patient's participation duration: 62 weeks (SOC Arm), 66 weeks (Vit-D Arm)&#xD;
&#xD;
        -  Statistical analysis:&#xD;
&#xD;
      The superiority of the vitamin D arm will be tested against the standard PEG IFN + RBV&#xD;
      combination. 260 patients in each arm will give 80% power to document a 12% difference in the&#xD;
      SVR rates between the experimental (Vitamin D) and the control (standard treatment) arms..&#xD;
&#xD;
      A futility analysis is planned for this study, in order to be able to interrupt the trial&#xD;
      prematurely in case preliminary results show a lack of efficacy of vitamin D.&#xD;
&#xD;
      This analysis will be performed on half of the patients, thus 260 patients (130 patients per&#xD;
      arm), on a week 12/14 week criterion (HCV RNA viral load at W12/W14).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study objectives were considered as obsolete regarding the new AAD arrival&#xD;
  </why_stopped>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with Sustained Virological Response (SVR).</measure>
    <time_frame>60 Weeks after peg-IFN/RBV initiation</time_frame>
    <description>Proportion of patients with Sustained Virological Response (SVR) as defined by HCV RNA below the detection limit based on quantitative PCR 12 weeks after stopping treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid Virological Response (RVR)</measure>
    <time_frame>4 Weeks after peg-IFN/RBV initiation</time_frame>
    <description>HCV RNA at 4 weeks post initiation of combination therapy (PEG IFN + RBV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Virological Response (EVR)</measure>
    <time_frame>12 Weeks after peg-IFN/RBV initiation</time_frame>
    <description>HCV RNA at 12 weeks post initiation of combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Treatment Response (ETR)</measure>
    <time_frame>48 Weeks after peg-IFN/RBV initiation</time_frame>
    <description>HCV RNA at end of treatment (week 48)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of ALT during treatment and 12 weeks after the end of treatment</measure>
    <time_frame>From 2 Weeks after peg-IFN/RBV initiation to End of Follow-up (Week 60)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAE) grade 3 and 4 (ANRS scale)</measure>
    <time_frame>From Lead-in phase (Week -4) to End of Follow-up (Week 60)</time_frame>
    <description>incidence of SAE leading to dosage reduction or treatment cessation, percentage of patients treated by EPO and G-CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of FibroScan values between pre-inclusion and week 60</measure>
    <time_frame>At Screening Visit 2 (S2) and at End of Follow-up (Week 60)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Pegylated Interferon Alpha 2b + Ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin</intervention_name>
    <description>Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>Vidrop</other_name>
    <other_name>PegIntron</other_name>
    <other_name>Rebetol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Common with National Program for Viral Hepatitis&#xD;
&#xD;
          -  Age: 18 years to 60 years&#xD;
&#xD;
          -  Positive HCV antibodies using a third generation test&#xD;
&#xD;
          -  Detectable HCV RNA by PCR&#xD;
&#xD;
          -  Liver biopsy showing chronic hepatitis with either a METAVIR score F1 with elevated&#xD;
             liver enzymes or scores F2/F3&#xD;
&#xD;
          -  Naïve to treatment with PEG-IFN and RBV&#xD;
&#xD;
          -  HBs antigen negative&#xD;
&#xD;
          -  Prothrombin time ≥60 %, normal bilirubin, alpha-foeto protein &lt; 3*normal range of the&#xD;
             laboratory, anti-nuclear antibodies&lt;1/160 Effective contraception during the treatment&#xD;
             period; no breast-feeding&#xD;
&#xD;
        Specific to the trial&#xD;
&#xD;
          -  Prior approval from the Ministry of Health to be treated as part of the National&#xD;
             Program with allocation to Peg-IFN α2b treatment&#xD;
&#xD;
          -  Living &lt;100 km from Cairo and able to come to the centre every week for the treatment&#xD;
&#xD;
          -  Signed informed consent and willingness to participate in the trial&#xD;
&#xD;
          -  Naïve to treatment with vitamin D (received vitamin D less than 30 consecutive days in&#xD;
             the 3 months preceding inclusion)&#xD;
&#xD;
          -  Biopsy slide validated by NHTMRI pathologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Common with National program for Viral Hepatitis&#xD;
&#xD;
          -  Serious co-morbid conditions such as severe hypertension, heart failure, significant&#xD;
             coronary heart disease, poorly controlled diabetes (HbA1C&gt;8%) , chronic obstructive&#xD;
             pulmonary disease&#xD;
&#xD;
          -  Major uncontrolled depressive illness&#xD;
&#xD;
          -  Solid transplant organ (renal, heart, or lung)&#xD;
&#xD;
          -  Untreated thyroid disease&#xD;
&#xD;
          -  History of previous anti-HCV therapy&#xD;
&#xD;
          -  Body mass index (BMI) greater than 30 kg/m²&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) coinfection: although HIV testing will not be&#xD;
             proposed or done, patients with known HIV coinfection will not be included in the&#xD;
             trial&#xD;
&#xD;
          -  Anti-HCV therapy contraindications:&#xD;
&#xD;
          -  hypersensitivity to one of the two drugs (PEG-IFN, RBV)&#xD;
&#xD;
          -  pregnancy or unwilling to comply with adequate contraception&#xD;
&#xD;
          -  breast-feeding&#xD;
&#xD;
          -  neutropenia (&lt;1500/mm3)&#xD;
&#xD;
          -  anaemia (&lt;11g/dL for women ; &lt;12g/dL for men)&#xD;
&#xD;
          -  thrombocytopenia (&lt;100,000/mm3)&#xD;
&#xD;
          -  elevated creatinin (&gt;1.5mg/dL)&#xD;
&#xD;
          -  concomitant liver disease other than hepatitis C (immuno-active chronic hepatitis B,&#xD;
             autoimmune hepatitis, alcoholic liver disease, hemochromatosis, alpha-1 antitrypsin&#xD;
             deficiency, Wilson disease)&#xD;
&#xD;
          -  liver biopsy showing severe steatosis (&gt;66%) and steatohepatitis; decompensated&#xD;
             cirrhosis (Child Pugh&gt;A); hepatocellular carcinoma, METAVIR score F4.&#xD;
&#xD;
          -  TSH&gt;5 mU/L&#xD;
&#xD;
        Specific to the trial&#xD;
&#xD;
          -  Patients allocated to Peg-IFN alpha 2a treatment&#xD;
&#xD;
          -  Hypersensitivity to vitamin D&#xD;
&#xD;
          -  Vitamin D contraindications:&#xD;
&#xD;
          -  hypercalcaemia (fasting calcaemia &gt;105 mg/L or 2.62 mmol/L)&#xD;
&#xD;
          -  ratio calciuria / creatininuria (fasting ratio &gt;1 mmol Ca/mmol creatinin)&#xD;
&#xD;
          -  hyperphosphatemia (&gt;1.5 mmol/L)&#xD;
&#xD;
          -  calcium lithiasis&#xD;
&#xD;
          -  patients being treated with thiazide diuretics (risk of hypercalcaemia with vitamin D&#xD;
             treatment)&#xD;
&#xD;
          -  patients being treated with glucocorticoïds (decrease in vitamin D efficacy)&#xD;
&#xD;
          -  postmenopausal women treated by vitamin D and calcium for osteoporosis&#xD;
&#xD;
          -  Treatment by vitamin D more than 30 consecutive days in the 3 months preceding&#xD;
             inclusion in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gamal Esmat, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NHTMRI, Cairo, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnaud Fontanet, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Pasteur, Paris France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NHTMRI</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>March 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C - Genotype 4</keyword>
  <keyword>SVR (Sustained Virological Response)</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Treatment Naïve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

